TY - JOUR
T1 - Sex-related characteristics and short-term outcomes of patients undergoing transcatheter tricuspid valve intervention for tricuspid regurgitation
AU - Scotti, Andrea
AU - Coisne, Augustin
AU - Taramasso, Maurizio
AU - Granada, Juan F.
AU - Ludwig, Sebastian
AU - Rodés-Cabau, Josep
AU - Lurz, Philipp
AU - Hausleiter, Jörg
AU - Fam, Neil
AU - Kodali, Susheel K.
AU - Rosiene, Joel
AU - Feinberg, Ari
AU - Pozzoli, Alberto
AU - Alessandrini, Hannes
AU - Biasco, Luigi
AU - Brochet, Eric
AU - Denti, Paolo
AU - Estévez-Loureiro, Rodrigo
AU - Frerker, Christian
AU - Ho, Edwin C.
AU - Monivas, Vanessa
AU - Nickenig, Georg
AU - Praz, Fabien
AU - Puri, Rishi
AU - Sievert, Horst
AU - Tang, Gilbert H.L.
AU - Andreas, Martin
AU - Von Bardeleben, Ralph Stephan
AU - Rommel, Karl Philipp
AU - Muntané-Carol, Guillem
AU - Gavazzoni, Mara
AU - Braun, Daniel
AU - Koell, Benedikt
AU - Kalbacher, Daniel
AU - Connelly, Kim A.
AU - Juliard, Jean Michel
AU - Harr, Claudia
AU - Pedrazzini, Giovanni
AU - Russo, Giulio
AU - Philippon, François
AU - Schofer, Joachim
AU - Thiele, Holger
AU - Unterhuber, Matthias
AU - Himbert, Dominique
AU - Alcázar, Marina Ureña
AU - Wild, Mirjam G.
AU - Windecker, Stephan
AU - Jorde, Ulrich
AU - Maisano, Francesco
AU - Leon, Martin B.
AU - Hahn, Rebecca T.
AU - Latib, Azeem
N1 - Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
PY - 2023/3/7
Y1 - 2023/3/7
N2 - AIMS: The impact of sexuality in patients with significant tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI) is unknown. The aim of this study was to investigate sex-specific outcomes in patients with significant TR treated with TTVI vs. medical therapy alone. METHODS AND RESULTS: The Transcatheter Tricuspid Valve Therapies (TriValve) registry collected data on patients with significant TR from 24 centres who underwent TTVI from 2016 to 2021. A control cohort was formed by medically managed patients with ≥severe isolated TR diagnosed in 2015-18. The primary endpoint was freedom from all-cause mortality. Secondary endpoints were heart failure (HF) hospitalization, New York Heart Association (NYHA) functional status, and TR severity. One-year outcomes were assessed for the TriValve cohort and compared with the control cohort with the inverse probability of treatment weighting (IPTW). A total of 556 and 2072 patients were included from the TriValve and control groups, respectively. After TTVI, there was no difference between women and men in 1-year freedom from all-cause mortality 80.9% vs. 77.9%, P = 0.56, nor in HF hospitalization (P = 0.36), NYHA Functional Classes III and IV (P = 0.17), and TR severity >2+ at last follow-up (P = 0.42). Multivariable Cox-regression weighted by IPTW showed improved 1-year survival after TTVI compared with medical therapy alone in both women (adjusted hazard ratio 0.45, 95% confidence interval 0.23-0.83, P = 0.01) and men (adjusted hazard ratio 0.42, 95% confidence interval 0.18-0.89, P = 0.03). CONCLUSION: After TTVI in high-risk patients, there were no sex-related differences in terms of survival, HF hospitalization, functional status, and TR reduction up to 1 year. The IPTW analysis shows a survival benefit of TTVI over medical therapy alone in both women and men.
AB - AIMS: The impact of sexuality in patients with significant tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI) is unknown. The aim of this study was to investigate sex-specific outcomes in patients with significant TR treated with TTVI vs. medical therapy alone. METHODS AND RESULTS: The Transcatheter Tricuspid Valve Therapies (TriValve) registry collected data on patients with significant TR from 24 centres who underwent TTVI from 2016 to 2021. A control cohort was formed by medically managed patients with ≥severe isolated TR diagnosed in 2015-18. The primary endpoint was freedom from all-cause mortality. Secondary endpoints were heart failure (HF) hospitalization, New York Heart Association (NYHA) functional status, and TR severity. One-year outcomes were assessed for the TriValve cohort and compared with the control cohort with the inverse probability of treatment weighting (IPTW). A total of 556 and 2072 patients were included from the TriValve and control groups, respectively. After TTVI, there was no difference between women and men in 1-year freedom from all-cause mortality 80.9% vs. 77.9%, P = 0.56, nor in HF hospitalization (P = 0.36), NYHA Functional Classes III and IV (P = 0.17), and TR severity >2+ at last follow-up (P = 0.42). Multivariable Cox-regression weighted by IPTW showed improved 1-year survival after TTVI compared with medical therapy alone in both women (adjusted hazard ratio 0.45, 95% confidence interval 0.23-0.83, P = 0.01) and men (adjusted hazard ratio 0.42, 95% confidence interval 0.18-0.89, P = 0.03). CONCLUSION: After TTVI in high-risk patients, there were no sex-related differences in terms of survival, HF hospitalization, functional status, and TR reduction up to 1 year. The IPTW analysis shows a survival benefit of TTVI over medical therapy alone in both women and men.
KW - Sex
KW - Transcatheter tricuspid valve intervention
KW - Tricuspid regurgitation
UR - http://www.scopus.com/inward/record.url?scp=85150000398&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150000398&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehac735
DO - 10.1093/eurheartj/ehac735
M3 - Article
C2 - 36445158
AN - SCOPUS:85150000398
SN - 0195-668X
VL - 44
SP - 822
EP - 832
JO - European heart journal
JF - European heart journal
IS - 10
ER -